

The role of TNF- α and TNF- β gene polymorphisms in the pathogenesis of rheumatoid arthritis

Hannan Al-Rayes¹, Misbahul Arfin², Mohammad Tariq², Abdulrahman Al-Asmari²

¹ Department of Medicine, Armed Force Hospital, Saudi Arabia

² Research Centre, Armed Force Hospital, Saudi Arabia

Abstract

Rheumatoid arthritis (RA) is a chronic systemic inflammatory disorder of unknown etiology that affects the synovial membrane of multiple joints. The clinical presentation of RA may vary from mild to severe with excessive erosions of periarticular bone leading to the loss of functional capacity. Both genetic and environmental factors are important in the development of this disorder. The genetic contribution to susceptibility for RA is underlined by a three- to four-fold higher concordance percentage for clinically expressed disease in monozygotic twins compared to dizygotic twins. The severity and long term outcome of RA have also been related to various genetic factors. Tumor necrosis factor (TNF), a pro-inflammatory cytokine, is involved in the pathogenesis of a variety of autoimmune disorders, including RA. A large number of studies have been undertaken to determine the role of TNF- α promoter polymorphisms in the pathogenesis of RA. On the other hand few attempts have been made to identify the association between TNF- α (lymphotoxin- α) polymorphism and RA. In this narrative review of published literature, an attempt has been made to determine the association between TNF- α promoter polymorphisms at positions -308, -238, -489, -857, -863 and TNF- β at +252 with respect to susceptibility to and severity of RA, as well as response to drug therapy. In spite of intra- and inter-ethnic variations, analysis of data suggests a significant role of TNF- α /TNF- β polymorphisms in determining the susceptibility/severity of RA and responsiveness to anti-TNF drug therapy. The TNF gene polymorphisms may be an interesting target for novel strategies to prevent RA and/or in its early treatment. Further studies using larger samples are needed to pinpoint the regulatory polymorphisms or haplotypes and their effects on the development of certain manifestations in RA.

Keywords

Tumor necrosis factor (TNF); Rheumatoid arthritis; Polymorphism; Saudi

Corresponding authors

Dr. Abudlrahman Al-Asmari
Senior Consultant and Director of Research Center
Armed Forces Hospital
P. O. Box 7897 Riyadh 11159, Saudi Arabia
abdulrahman.alasmari@gmail.com
Tel.: 966 1 4777714 ext. 25100
Fax: 966 1 4777714 ext. 23066

Disclosure

The authors have no conflict of interests or financial disclosures.

Introduction

Rheumatoid arthritis (RA, MIM#180300) is a chronic inflammatory autoimmune disorder with a prevalence of around 1% in the world's most populations. RA occurs when the body's immune defenses attack the tissue in the joints, leading to pain and degeneration of the articular cartilage. Arthritis usually begins in the small joints of the hands and feet, spreading later to the larger joints. The inflamed joints lining or synovium extends and then erodes the articular cartilage and bone, causing joint deformity and progressive physical disability. Extra-articular features include nodules, pericarditis, pulmonary fibrosis, peripheral neuropathy, and amyloidosis. Besides RA disease, side effects of drugs used for its treatment may also increase mortality and morbidity, and as a result patients with RA have a shorter life expectancy than their healthy peers. Drugs used to limit the symptoms have limited effect and do not improve the long term prognosis. The results are reduced quality of life, loss of working capacity, and subsequent invalidity.

The etiological factors underlying RA are not yet fully understood. During active RA, inflammatory cells such as monocytes/macrophages, mast cells, T cells, and B cells infiltrate the synovial joints. The immune cells interact in a complex and intricate manner leading to the release of pro-inflammatory mediators [1]. Cytokines, a group of modulatory proteins or glycoproteins produced by a wide range of cells in response to a variety of stimuli, are important mediators and regulators of synovial inflammation [2]. Basal and cell-stimulated cytokine levels differ between individuals; both genetic and environmental influences have been shown to play a role in their variability [3]. High levels of pro-inflammatory cytokines including tumor necrosis factor- α (TNF- α), interleukin (IL)-1, and IL-17 are detectable in the joint fluids and synovium of RA patients. These pro-inflammatory mediators have been demonstrated to play a vital role in the initiation and development of RA [4,5]. Abundant expression of pro- and anti-inflammatory cytokines observed in the affected tissues and serum of RA patients clearly indicates the involvement of cytokines in the etiopathology of RA [6].

Multi-factorial origins have been suggested for RA, indicating that environmental factors as well as the contributions of several genes appear to play a role in the development of the disease. The genetic component is emphasized by a 3-4 fold higher concordance rate in monozygotic compared to dizygotic twins [7-9]. The severity and long term outcome of RA have also been related to various genetic factors. Linkage studies in RA families and genome wide screening in case control studies have identified a large number of validated genetic loci associated with RA [10-18]. HLA-DRB1 is a major genetic component of RA across ethnicities and is estimated to contribute to 30-50% of the total genetic risk [19,20]. However, the other risk loci identified to date show ethnic-specific patterns of disease association [18,21-33]. Several cytokine genes have been considered as likely candidates for influencing susceptibility or severity of RA. Polymorphisms in these cytokine genes have been reported to be associated with RA [5,34-38].

Role of TNF- α and TNF- β in the pathogenesis of RA

Tumor necrosis factor (TNF), a pro-inflammatory cytokine, has been shown to play a pivotal role in the pathogenesis of several autoimmune diseases including RA [6,39,40]. This is further underlined by the development of several anti-cytokine drugs in the treatment of RA. In addition to inflammatory tissue destruction, factors involved in tissue repair and necrosis or apoptosis are likely to be involved in erosive disease and may also codetermine disease susceptibility. Both TNF- α , produced mainly by monocytes and activated macrophages, and TNF- β , produced mainly by activated T cells, play important immunoregulatory roles in various diseases. The genes for TNF- α (OMIM 191160) and TNF- β , also known as lymphotoxin- α (LT- α , MIM 153440), show close linkage to the HLA class I (*HLA-B*)

Population/Group	Genotype/Allele	Suggested association with RA	Reference
Saudis	GG/G	Susceptibility to RA	[48]
Egyptian	GG/G	Susceptibility to RA	[58]
Egyptian	A	Severity of RA	[58]
Egyptian	AA	Susceptibility to RA	[59]
Egyptian	GG	Severity of RA	[59]
Tunisian	G<A polymorphism	No association	[60]
Turkish	G<A polymorphism	Severity of RA	[61]
Turkish	G<A polymorphism	No association	[62]
Iranian	G<A polymorphism	No association	[63]
Serbian	G<A polymorphism	No association	[64]
Portuguese	GA	Severity of RA	[65]
Portuguese	GA/AA	No association with JIA	[66]
Czech	A	No association	[61]
Czech	A	Severity of RA	[67]
German	G<A polymorphism	No association	[68]
German	G	Protective to JIA	[69]
Polish	G<A polymorphism	No association	[70]
Polish	G<A polymorphism	No association	[71]
Indian	A	Protective to RA	[6]
Taiwanese	A	Protective to RA	[72]
Taiwanese	G<A polymorphism	No association	[73]
Han Chinese	A	Protective to RA	[47]
Japanese	G	Susceptibility to RA	[74]
Hungarian	A	Susceptibility to RA	[75]
Chilean	A	Susceptibility to RA	[76]
Spanish	A	Susceptibility to RA	[77]
Spanish	A	Susceptibility to RA	[78]
Spanish	G<A polymorphism	Severity of RA	[79]
Spanish	G<A polymorphism	No association with severity	[80]
Finnish	GG	Susceptibility	[81]
Swedish	G	Susceptibility to RA	[82]
Dutch	G<A polymorphism	No association	[83]
Dutch	A	Associated with severity	[84]
Caucasian	A	Susceptibility to RA	[85]
Caucasian	G<A polymorphism	No association	[86]
Caucasian	A	Susceptibility to RA	[87]
Caucasian	GG	No association	[88]
Caucasian	G<A polymorphism	No association	[89]
Mexican	A	Susceptibility to RA	[24]
Mexican	A	Susceptibility to RA	[78]
Mexican	A	Susceptibility to JRA	[90]
American	G<A polymorphism	Severity of RA	[46]
Slovanian	A	Low severity of RA	[91]
Latin American	G<A polymorphism	Susceptibility to RA	[92]
European	G<A polymorphism	No association	[92]
Several populations	A	Susceptibility to RA	[93]

Table I. Association of TNF- α -308 polymorphism in etiopathogenesis of RA in various populations

JIA = juvenile idiopathic arthritis; JRA = juvenile rheumatoid arthritis; RA = rheumatoid arthritis

and class II (*HLA-DR*) genes. TNF- α and TNF- β are closely related cytokines that share 30% amino acid residues and use the same cell surface receptor [41]. Nedwin et al. [42] reported that the TNF- α and TNF- β genes are located in tandem on chromosome 6 (chromosome 6p21.1-6p21.3). Studies on monozygotic twins and their first-degree relatives, using *ex vivo* endotoxin stimulated whole blood samples, have provided evidence that 60% of variation in the production capacity of TNF- α appears to be genetically determined [43]. Several polymorphisms within the promoter region of TNF- α and the intron 1 polymorphism of TNF- β , in particular, have been associated with altered levels of circulating TNF- α [44,45].

TNF- α -308 polymorphism and RA

The search for genetic heterogeneity within the TNF- α gene has disclosed several polymorphisms in the promoter region. TNF- α promoter polymorphisms have been widely studied as a possible risk factor for the onset, progression, and severity of RA. The review of the literature suggests that polymorphisms in TNF- α promoter such as TNF- α G308A (rs1800629), TNF- α G238A (rs361525), TNF- α G376A (rs3093659), TNF- α G489A (rs180061), TNF- α T857C (rs1799724), and TNF- α A863C (rs1800630) might be involved in the pathogenesis of RA.

Among all the polymorphisms of TNF- α gene identified by Polymerase Chain Reaction-Single Strand Conformational Polymorphism (PCR-SSCP) analysis, TNF- α -308 polymorphism has been studied most and reported to be associated with several autoimmune diseases including RA [46-48]. The genetic variation on position -308 results in two allelic forms in which the presence of guanine (G) defines the common variant and the presence of adenine (A) defines the less common one. TNF- α -308A allele displays increased gene transcription as compared to the common allele G. It has been shown to produce 6-7 fold higher levels of TNF- α transcription [49-53].

TNF- α -308 polymorphism and susceptibility to RA

TNF- α -308 polymorphism is associated with elevated TNF levels, enhanced susceptibility, and poor prognosis in several diseases [54-57]. The narrative review of several studies undertaken to determine the association of TNF- α polymorphisms -308 and RA in different parts of the world is presented in Table I.

The results of the studies on association of TNF- α polymorphism with RA are inconsistent. The differences in findings have been attributed to variation in ethnicity, sample size and method of diagnosis [95-97]. Recently, we reported significantly lower frequency of -308A allele and higher frequency of -308G allele in Saudi RA patients as compared to healthy controls [48]. We concluded that -308A allele of TNF- α may exert a protective influence for the development of RA whereas allele G and genotype GG might be a risk factor among Saudi patients. Our findings on Saudi patients are supported by earlier reports on other ethnic groups, including Taiwan Chinese [72], Japanese [74], Swedish [82], Finnish [81], Hungarian [75], Han population of Eastern China [47], Egyptian [58], and Indian [6].

Contrary to these findings, numerous investigations showed significantly higher frequency of allele A or genotype AA in RA patients as compared to control group suggesting that TNF- α -308A is a predisposing factor among Caucasian [85,87], Mexican [24,78,90], Spanish [77-79], American [46], Dutch [84], Egyptian [59], Portuguese [66], Czech [67], and Serbian population [64].

On the other hand, no significant association between TNF- α -308 polymorphism and RA susceptibility was observed in Taiwanese [73], Polish [70,71], Iranian [63], Turkish [61,62], European [92], Tunisian [60], Czech [61], German [68], Spanish [80], Chilean [76], and Caucasians [86,88,89]. The exact reason for such variations in the distribution of alleles and genotypes of TNF- α -308 polymorphism in RA patients in different ethnic groups is far from clear. These differences may be attributed to the eth-

nicity-related genetic makeup in different populations, which is evident from the highly significant variations in genotype data of TNF- α -308 polymorphism among the healthy subjects of various ethnicities (Table II). Lee et al. [92] also suggested that ethnicity has a significant impact on the genotype distribution of TNF- α -308 polymorphism in RA patients. RA is considered to be a complex disorder and its onset and severity are influenced by genetic as well as environmental factors. Hence, the gene-environment interaction might be responsible for the significant differences in the results of polymorphism association studies on RA patients from various ethnicities/geographical locations.

TNF- α -308 polymorphism and severity of RA

The -308A allele is associated with high levels of TNF- α , suggesting that a genetic predisposition to produce higher levels of TNF- α might contribute to subsequent development of erosions and radiographic damage. Significantly increased levels of TNF- α have been observed in arthritis synovial fluid [110], and inhibition of TNF- α using a TNF receptor fusion protein markedly improves skin and joint inflammation in RA patients [111]. The association of the alleles and genotypes of TNF- α -308 polymorphism has been reported with severity of RA in American, Mexican, and Czech populations [24,46,67].

Khanna et al. [46] found an association between TNF- α -308 polymorphism and progression of radiographic damage in American patients with early seropositive RA, and suggested that the association might be dependent on genetic variants in linkage disequilibrium with TNF- α -308A allele and DRB1*0301. Rodríguez-Carreón et al. [24] also found an association between TNF- α -308A allele and severity of RA in Mexicans which was independent from HLA-DR alleles. Nemeč et al. [67] found no difference in the distribution of genotypes and alleles frequencies of TNF- α -308 between the Czech RA patient and control groups. However, on dividing the RA group according to the radiographical progression of disease, a significant difference in the distribution of genotypes was noticed, suggesting that GG genotype of TNF- α -308 polymorphism is associated with the severity of RA in Czech population. Wilson et al. [86] reported that RA patients with allele A tend to have an increased number of erosions. Vinasco et al. [79] did not find any correlation between RA and TNF- α -308 promoter polymorphism, but they found an increased frequency of nodulosis among patients with the allele A. The GA genotype of TNF -308 polymorphism has been reported to be associated with joint erosions in German polyarthritis patients [69]. Similarly, Rezaieyazdi et al. [63] also suggested that TNF- α -308 polymorphism may be associated with radiographic damage in Iranian RA patients.

Population/ Group	Genotype Frequencies (%)			Reference
	GG	GA	AA	
Saudis	50.0	38.09	11.90	[48]
American	68.2	29.1	2.7	[98]
Australian	58.0	39.0	3.0	[99]
Chilean	83.1	16.3	0.6	[100]
Chilean	90	10	0	[76]
Chinese	85.6	13.3	1.1	[47]
Chinese	83.2	15.7	1.1	[101]
Czech	80.66	19.33	0.0	[67]
Danish	65.8	30.5	3.7	[102]
Dutch	56.6	38.6	4.5	[83]
English	59.6	37.4	3.0	[103]
Finnish	68.8	30.0	1.3	[81]
French	81.6	17.2	1.2	[104]
German	67.0	28.0	5.0	[105]
German	67.35	31.12	1.53	[69]
Iranian	96.7	3.3	0.0	[63]
Japanese	97.0	3.0	0.0	[106]
Macedonian	76.8	21.9	1.3	[107]
Mexican	91.4	8.6	0.0	[24]
Spanish	82.4	15.7	1.9	[79]
Swedish	56.5	40.5	3.0	[108]
Taiwanese	83.4	15.8	0.8	[73]
Turkish	82.79	17.21	0	[62]
West African	81.6	17.0	1.4	[109]

Table II. Genotype distribution of TNF- α -308 promoter polymorphism in different healthy groups

Contrary to these, no significant association between erosive disease and TNF- α polymorphism was found in Turkish patients [62]. Absence of any association between the TNF- α polymorphism and clinical manifestations or severity of RA has also been reported by other investigators [48,70,86,112]. In a 5-year follow-up study on British polyarthritis patients no association between TNF- α promoter polymorphism and severity of radiographic erosions was observed [112]. A study on Polish RA patients also failed to show any correlation between TNF- α -308 polymorphism and radiological progression of the disease [70].

TNF- α -238 polymorphism and RA

The association between TNF- α G238A polymorphism and several inflammatory diseases including systemic lupus erythematosus [113], juvenile onset psoriasis, and psoriatic arthritis [114], scarring trachoma [109], and an alcoholic steatohepatitis has been reported. However, meta-analysis of the data on the role of TNF- α -238 polymorphism in RA has yielded inconclusive results (Table III).

Several studies showed significant association of allele G or genotype GG of TNF- α 238 polymorphism with RA susceptibility or severity [24,83,89,107,115-117], while others showed an association of allele A or genotype GA with susceptibility/severity of RA/JRA [69,90,118]. On the other hand, some studies showed no significant association of any allele/genotype of TNF- α 238 polymorphism with RA [47,61,62,68,72,78,79].

It has been shown that the variables like ethnicity, age, and gender might play a significant role. In a case-control study, a significant association was reported between the TNF -238GG genotype and earlier onset and severity of RA in Dutch population [83]. These investigators identified the TNF -238GG

Population/Group	Genotype/Allele	Suggested association with RA	Reference
Mexican	GG	Susceptibility to RA	[24]
Mexican	G<A polymorphism	No association	[78]
Mexican	GA	Association with JRA	[90]
Macedonian	A	Protective to RA	[107]
Italian	GG	Susceptibility to RA	[115]
German	A	Susceptibility to JIA	[69]
German	G<A polymorphism	No association with RA & JRA	[68]
Turkish	G<A polymorphism	No association with JIA	[61]
Turkish	G<A polymorphism	No association	[62]
Spanish	G<A polymorphism	No association	[79]
Dutch	GA	Protective to RA	[83]
Dutch	GG	Severity of RA	[116]
Caucasian	G	Susceptibility to JIA	[117]
Caucasian	GG	Susceptibility to RA	[89]
Chinese	G<A polymorphism	No association	[47]
Taiwanese	G<A polymorphism	No association with severity	[72]
Syrian	G<A polymorphism	Association with severity	[118]

Table III. Association of TNF- α -238 polymorphism in etiopathogenesis of RA in various populations

JIA = juvenile idiopathic arthritis; JRA = juvenile rheumatoid arthritis; RA = rheumatoid arthritis

Population/Group	Genotype/Allele	Polymorphism	Suggested association with RA	Reference
Turkish	G<A polymorphism	TNF- α -376	No association	[62]
Taiwanese	G<A polymorphism	TNF- α -376	No association	[72]
Caucasian	G<A polymorphism	TNF- α -376	No association with JIA	[117]
Caucasian	G<A polymorphism	TNF- α -376	No association	[89]
Dutch	G<A polymorphism	TNF- α -376	No association	[83]
Dutch	GG	TNF- α +489	Susceptibility to RA	[34]
Italian	AA	TNF- α +489	Protective to RA	[115]
European	A	TNF- α +489	No association	[121]
Caucasian	A	TNF- α +489	Susceptibility to JIA	[117]
Canadian	A	TNF- α +489	Susceptibility to RA	[122]
German	C<T polymorphism	TNF- α -857	No association with RA/JRA	[68]
Caucasian	T	TNF- α -857	Susceptibility to RA in male	[85]
Caucasian	C<T polymorphism	TNF- α -857	No association with JIA	[117]
Caucasian	C<T polymorphism	TNF- α -857	No association	[89]
Chinese	C<T polymorphism	TNF- α -857	No association	[47]
Taiwanese	C<T polymorphism	TNF- α -857	No association	[72]
Japanese	T	TNF- α -857	Susceptibility to JRA	[123]
Japanese	T	TNF- α -857	Susceptibility to RA	[74]
Japanese	C<T polymorphism	TNF- α -857	Association with severity	[124]
Thai	CA	TNF- α -863	Susceptibility to RA	[125]
Chinese	C<A polymorphism	TNF- α -863	No association	[47]
Taiwanese	C<A polymorphism	TNF- α -863	No association with severity	[72]
Turkish	CC	TNF- α -863	Susceptibility to JIA	[126]
Japanese	A	TNF- α -863	Susceptibility to JRA	[123]
Japanese	C<A polymorphism	TNF- α -863	Association with severity	[124]
Caucasian	A	TNF- α -863	Association with severity	[127]
Caucasian	C<A polymorphism	TNF- α -863	No association with JIA	[117]
Caucasian	C<A polymorphism	TNF- α -863	No association	[89]
Indian	A	TNF- α -863	Earlier onset in females	[6]
Japanese	T<C polymorphism	TNF- α -1031	Severity of RA	[124]
Japanese	C	TNF- α -1031	Susceptibility to JRA	[123]
Caucasian	T<C polymorphism	TNF- α -1031	No association with JIA	[117]
Caucasian	A	TNF- α +851	Susceptibility to JIA	[117]
Caucasian	A<G polymorphism	TNF- α +1304	No association with JIA	[117]
Dutch	Polymorphism	TNF- α +70	No association	[83]
Spanish	TNF-a6, b5	TNF- α microsatellite	Susceptibility to RA	[128]
Colombian	TNF-a6 allele, TNF-b4 allele	TNF- α microsatellite	Susceptibility to RA	[129]
Indian	TNF-b5 allele	TNF- α microsatellite	Susceptibility to RA	[130]

Table IV. Association of TNF- α polymorphism at various loci in etiopathogenesis of RA in various populations

JIA = juvenile idiopathic arthritis; JRA = juvenile rheumatoid arthritis; RA = rheumatoid arthritis; TNF = tumor necrosis factor

genotype as a genetic factor that contributes to radiologically detected erosions in RA patients. Considering the location of this polymorphism in a region involved in TNF- α gene transcription and its association with disease, they hypothesized that the -238G-to-A transition might influence TNF- α mRNA expression and, as a result, facilitate deregulation of the cytokine network, thereby influencing the disease process. In order to extend the association between the TNF -238 promoter polymorphism and the severity of RA, this group of investigators further reported that the TNF -238GG genotype contributes to the progression of joint destruction in RA, independent from HLA-DR4 [116]. Fabris et al. also suggested that TNF -238GG genotype associates with severity of RA, as TNF -238GA genotype was absent in severe but present in mild RA Italian patients [115].

Similarly, Rodríguez-Carreón et al. [24], studying Mexican RA patients versus healthy subjects, showed statistically significant difference in TNF- α -238GA genotype in two groups and reported that TNF- α -238A allele is a risk factor for RA in adulthood. Emonts et al. [89] also reported that the genotype TNF- α -238 G/A polymorphism was significantly associated with RA. These investigators concluded that the TNF- α -238 G/G genotype is overrepresented in RA patients when compared to controls (crude OR (95% CI) 2.48 (1.38-4.46) for TNF- α G/G vs. G/A). Since RA patients were significantly older than healthy controls and controls are by definition still “at risk” to develop RA at a later age, the difference observed may also result from a difference in susceptibility to develop RA at a younger age. Recently, Lee et al. [119] reported that the TNF- α promoter -238A/G polymorphism was not associated with susceptibility to juvenile idiopathic arthritis (JIA) in Europeans, while Jiménez-Morales et al. [90] reported that the TNF- α -238A allele has an association with JRA only in males and supported the concept that the TNF- α gene is a genetic risk factor for JRA in the pediatric Mexican population. The causes for such variation in the published results from different populations are far from clear. The discrepancy of results has been attributed to the following reasons. First, genetic heterogeneity for JIA may exist in different populations. The prevalence of the A allele was found to vary among healthy controls of several ethnic groups from 4.1 to 26.9%. Its frequency was lowest among Mexicans and highest among Turks. Second, there are clinical heterogeneities or variations in sub-type of disease. Third, discrepancies may be caused by different linkage disequilibrium (LD) patterns, for example, these polymorphisms may be in LD with a nearby causal variant in one ethnic group but not in another [68,69,120].

TNF- α -376 polymorphism and susceptibility to RA

Only a few reports are available on the role of TNF- α -376 polymorphism and RA (Table IV), however the results are consistent showing no statistically significant association between TNF- α -376 polymorphism and RA in Chinese, Turkish, Caucasian, Spanish, and Taiwanese patients [47,62,72,89,117]. Emonts et al. [89] found significant difference in the frequency of GG genotype among the RA patients and controls ($p = 0.04$) however, on applying Bonferroni correction for multiple testing, the data were not significant. Further, the frequency of the TNF- α -376A alleles in the RA multiplex families was similar in several studies [116,131], indicating that these alleles occur too infrequently to play a major role in RA susceptibility in these populations.

TNF- α +489 polymorphism and susceptibility to RA

TNF +489 polymorphism, located in the first intron of the TNF- α gene was described in 1996 [113]. Van Krugten et al. [34] demonstrated that TNF +489A allele is associated with a decreased risk of developing RA independent of SE. A similar conclusion came from others, who reported that the +489

polymorphism is not in linkage with HLA class II alleles associated with RA [113,132]. These investigators suggested an independent contribution of TNF- α +489 polymorphism in RA susceptibility. In a retrospective analysis of consecutively selected RA patients from the Leiden, Netherland, Van Krugten et al. [34] showed a significant association of the +489GA genotype and less erosive disease in comparison to patients with the GG genotype. On the other hand, the association of the TNF +489G allele with a more severe course in RA (independent of DR4-homozygosity) was reported by Verweij et al. [133]. Mullighan et al. [132] reported an association of the TNF +489A allele with TNF production. Preliminary data on the functional relevance of the +489 polymorphism using allele-specific transcript quantification analysis suggested no transcriptional difference between the TNF +489A and TNF +489G allele. Thus the disease associations may have to be explained by linkage disequilibrium with alleles within or nearby the TNF/LT locus. Collectively, published data suggested that the TNF +489 polymorphism is part of a haplotype that is associated with less severe disease in RA and so probably associated with less TNF production in the joints of RA patients [115,117,122]. However, Low et al. [121] did not support the association of the TNF +489A allele with RA susceptibility or severity (Table IV).

TNF- α –857 polymorphisms and susceptibility to RA

It has been reported that allele –857T is associated with higher production of TNF- α , whereas allele –857C is associated with low TNF levels [134]. However, the results of the published data about the association of TNF- α –857 polymorphism with TNF expression are quite inconsistent [134-137]. Yen et al. [72] reported that the TNF- α promoter polymorphisms at positions 857 was not related to the clinical manifestations of RA in Taiwanese patients. Further, no significant association between RA patients and either genotype or allele frequencies of the TNF- α –857 polymorphism was detected in Chinese [47]. Although TNF- α –857A has been shown to influence RA susceptibility in individuals monozygous for the SE in Caucasian population [85], Emonts et al. [89] suggested that after correction for age (and gender), and multiple testing, TNF- α –857 polymorphisms were not associated with RA susceptibility or severity in Caucasians. The frequency of –857T allele was significantly higher in Japanese patients with systemic JRA [123]. These investigators concluded that –857T allele in combination with HLA-DRB1 0405 haplotype may be a systemic risk factor for JRA [123,134]. Overall, the analysis of published data (Table IV) from different ethnic groups showed lack of association between TNF- α –857 and RA in the majority of ethnic groups [47,68,72,89,117]. The results of these studies warrant for additional larger studies to elucidate the contributing factor of these polymorphisms in the susceptibility to, and severity of, RA.

TNF- α –863 polymorphisms and susceptibility to RA

TNF- α –863A polymorphism has been reported to be associated with RA susceptibility in Japanese [123,124], Turkish [126], and Thai populations [125]. The frequency of TNF –863A allele in Japanese patients with systemic JRA was significantly higher than those in controls. These results suggested that allele –863A might be a predisposing factor for systemic JRA, due in part to the higher promoter activity of the TNF- α gene [123], as individuals with allele –863A have been reported to produce higher levels of TNF- α [134]. It was also reported that –863A allele of the TNF- α –863 polymorphism is in strong linkage with HLA-B61 and DRB0901, which are known to contribute to RA susceptibility [134]. Recently Gambhir et al. [6] reported that allele A of TNF- α –863 polymorphism is associated with early onset of RA in Indian females. Udalova et al. [127] also found that –863A was predictive of severe erosive joint disease in HLA-DR4-positive individuals in UK population.

Contrary to these reports, Yen et al. [72] reported that the TNF- α -863 polymorphisms were not related to clinical manifestations of RA in Taiwanese patients. Further, no significant association between RA patients and either genotype or allele frequencies of TNF- α -863 polymorphism was detected in the Chinese [47]. Emonts et al. [89] suggested that after correction for age (and gender), and multiple testing, TNF- α -863 polymorphism was not associated with RA susceptibility or severity in Caucasians. These investigators suggested additional larger studies in order to elucidate the contributing factor of this polymorphism in the susceptibility to, and severity of, RA.

TNF- β +252 polymorphism and RA

In view of the highly critical role of TNF- α promoter polymorphisms in the pathogenesis of RA, it is important to examine the role of other members of the major histocompatibility complex (MHC) class III region in the pathogenesis of RA. TNF- β belonging to the surrounding of TNF- α locus has indeed been shown to play important role in the pathogenesis of several autoimmune diseases, including RA [138,139]. Immunological studies on TNF- β showed its close resemblance to TNF- α in terms of pro-inflammatory and apoptotic activity.

A polymorphism has been reported at position +252 within the first intron of the TNF- β gene, consisting of nucleotides guanine (TNF- β +252G) on one allele and adenine (TNF- β +252A) on the alternate allele [54]. The presence of G at this position defines the mutant allele known as TNF- β *1 (allele 1) which is less frequent allele and is associated with higher TNF- α and TNF- β production [54,140]. TNF- β A252G polymorphism (rs909253) affects a phorbol ester-responsive element. Association of TNF- β +A252G polymorphism has been reported with various autoimmune diseases including RA [48,141-143], Graves' disease [144], idiopathic membranous glomerulonephritis, IgA nephropathy [145], myasthenia gravis [146], asthma diathesis [147], SLE with nephritis [148], systemic sclerosis [149], and plaque psoriasis [150]. Recently, TNF- β +A252G polymorphism is also reported to be associated with both susceptibility to, and mortality from, sepsis [151,152].

Although there is a plethora of literature regarding the role of TNF- α polymorphism in the pathogenesis of a variety of autoimmune diseases, including RA, only few studies have been reported on the role of TNF- β in the pathogenesis of RA. The outcome of published data about the association of TNF- β +252 polymorphism with RA has been summarized in Table V.

Recently, we have reported the role of TNF- β +252 promoter polymorphism in Saudi RA patients, that GG genotype was susceptible to RA while GA was refractory [48]. Earlier, we found an associa-

Population/Group	Genotype/Allele	Suggested association with RA	Reference
Saudi	GG	Susceptibility	[48]
Tunisian	GG/G	Susceptibility	[60]
Belgian	A<G polymorphism	No association	[153]
Caucasian	GG	Susceptibility	[138]
Caucasian	A	Susceptibility	[143]
Caucasian	GG	Early age of onset	[143]
Japanese	A	Susceptibility	[141]
Swedish	A<G polymorphism	No association	[154]
Spanish	A<G polymorphism	No association	[79]

Table V. Association of TNF- β +252 polymorphism in etiopathogenesis of RA in various populations

that GG genotype of TNF- β together with HLA-DRB1*04 might contribute to the RA susceptibility. Our findings are similar to the observation made on Caucasian and Japanese populations showing that TNF- β +252 polymorphism together with HLA-DRB1*0405 influences the susceptibility to RA [141,143].

Panoulas et al. [138] from UK and Karray et al. [60] from Tunisia also reported that GG genotype of TNF- β +252 polymorphism occurs more frequently in RA patients as compared to general population. The GG genotype has been linked with higher levels of TNF- β (LT- α) [155], and therefore the presence of erosions in RA may be partially caused by higher levels of TNF- β in the affected joint. However, both TNF- α and TNF- β genes are located in the same area of the genome, and the two polymorphisms are in linkage disequilibrium. It is thus possible that association of the TNF- β +252 polymorphism with RA disease could be due to linkage with the TNF- α -308 polymorphism or to linkage of both polymorphisms with another disease marker located nearby, since there is a strong association between RA and certain HLA haplotypes, the genes of which are located along with the TNF locus in the MHC region, and there is evidence that genes closely associated with the MHC region are operative in RA. As these polymorphisms segregate independently (so called "genetic heterogeneity"), any one individual might respond to an insult with a pattern of cytokine expression quite different from the cytokine response another individual might mount. As *in vivo* cytokine interactions are complex, it is unlikely that a single allelic variant results in etiopathogenesis of RA. However, the collective influence of several factors could influence immune responses as complex as those underlying in RA and other autoimmune disorders. Published data supported an important role of ethnicity in the association of TNF- α and TNF- β polymorphisms and RA.

Anti-TNF- α therapy response and TNF- α genotypes

Anti-tumor necrosis factor (anti-TNF) therapies have revolutionized the treatment of RA [156,157]. Three drugs of this type, infliximab, etanercept, and adalimumab, have been used with success in hundreds of thousands patients with RA around the world. New drugs targeting TNF are in development or have been recently approved [158]. The beneficial effects of these drugs include a better quality of life, control of inflammation, stiffness and pain, and slowing progression to joint erosions and deformity. However, there is a significant percentage of patients who do not obtain these advantageous effects [156-158]. In some of these patients, this lack of response is primary, from the start of the treatment, whereas others develop resistance to treatment after a period of initial response. To workout useful predictors to forecast what the clinical response of a specific patient will be, multiple lines of research are being undertaken based on clinical features of patients (such as synovial tissue biomarkers, blood proteins) or genetic variants [159-162]. Very promising, though preliminary, findings have been reported in the field of genetics. Sixteen single-nucleotide polymorphisms (SNPs) with an important association with response to treatment were identified in a recent genome-wide association study [159]. However to date, the only replicated genetic predictor of anti-TNF response is the -308 G>A single-nucleotide polymorphism in the TNF- α promoter region (Table VI).

The presence of the TNF -308GG genotype appears to be a marker of good response to anti-TNF treatment. Good responders were defined, according to the European League Against Rheumatism (EULAR) consensus statement, as patients whose DAS28 score improved by at least 1.2 at week 22 compared with their DAS28 score before the first infusion [184]. Similarly, non-responders were defined as patients whose DAS28 score improved by < 1.2 [184]. Various reports using different anti-TNF- α blockers suggested that the presence of the -308GG genotype or G allele of TNF- α -308 polymorphism may help to define a subgroup of RA patients with a better response to this treatment [164,168,171-175]. A recent meta-analysis of previous studies confirmed that carriage of the allele-G at TNF -308 is

associated with a better response to anti-TNF treatment in comparison with patients homozygous for the allele-A among Caucasians [163].

The percentage of good responders was significantly higher in group GG than in group AA and AG of TNF- α -308 polymorphism. The most straightforward interpretation of these data is that in AA and AG patients, standard infliximab treatment is overwhelmed by the high production of TNF- α associated with -308AG or AA genotypes. It could be argued that poor outcome with infliximab only

Population/Group	Genotype/allele	Polymorphism	Response to anti-TNF-therapy	Reference
Meta-analysis	G allele	TNF- α -308	Better response	[163]
Review	A allele	TNF- α -308	Poorer response	[164]
Review	G<A	TNF- α -308	Better response	[165]
Review	A allele	TNF- α -308	Poorer response	[92]
Review	A allele	TNF- α -308	Poor response	[166]
Meta-analysis	G<A	TNF- α -308	No association	[167]
Meta-analysis	G<A	TNF- α -238	Better response to infliximab	[67]
Swiss	GG	TNF- α -308	Better response	[168]
Caucasian	AA	TNF- α -308	Poor response to etanercept	[160]
Caucasian	GA	TNF- α -238	Poor response to infliximab	[160]
Caucasian	G<A	TNF- α -308	No association	[169]
Caucasian	G<A	TNF- α -238	No association	[169]
Caucasian	G<A	TNF- α -308	No association	[170]
French	GG	TNF- α -308	Better response to infliximab	[171]
French	GG	TNF- α -308	Better responder to etanercept	[172]
Chilean	GA	TNF- α -308	Better response to infliximab	[173]
Chilean	GG	TNF- α -308	Better response to adalimumab	[174]
Chilean	GG	TNF- α -308	Better response to adalimumab	[175]
Swedish	GG	TNF- α -308	Better response to etanercept	[176]
German	G<A	TNF- α -308	Better response to etanercept	[177]
Serbian	GG	TNF- α -308	Better response to etanercept	[178]
Serbian	A allele	TNF- α -308	Poor response to etanercept	[64]
Spanish	G<A	TNF- α -308	No influence on infliximab	[179]
Spanish	G<A	TNF- α -238	No influence on infliximab	[179]
Spanish	G<A	TNF- α -308	No influence on prednisone	[180]
Portuguese	GG	TNF- α -308	Better response to infliximab	[65]
Portuguese	GG	TNF- α -308	Poor response to etanercept	[65]
Korean	GG	TNF- α -308	Better response to etanercept	[181]
Hungarian	GG	TNF- α -308	Better response to infliximab	[75]
Swedish	GG	TNF- α -308	Better responder to etanercept	[176]
Polish	G<A	TNF- α -209	No influence on leflunomide	[182]
Caucasian	SNPs	LTA-TNF	Better response to etanercept	[183]
Italian	GG	TNF- α -238	No association	[115]

Table VI. Association of TNF- α polymorphism with anti-TNF- α therapy response in RA

indicates that the AG or AA genotypes are associated with particular severity in RA patients. Contrary to these findings, some Authors did not observe any difference in disease severity between patients in group AA and AG (poor infliximab responders) and those in group GG (good infliximab responders) before treatment with infliximab [171].

Maxwell et al. [160] evaluated efficacy of anti-TNF treatment in Caucasian RA patients. They demonstrated a complex relationship between genotype at TNF- α -238 and -308 as well as treatment response that appears to differ according to the agent used. The RA patients carrying the rare TNF -308AA genotype responded poorly to etanercept, whereas genotype at this SNP did not associate with response to infliximab. Conversely, genotype at TNF -238 was associated with treatment response to infliximab, but not etanercept.

These findings were confirmed in a secondary analysis of the same patients, comparing the frequency of EULAR good and non-responders according to TNF -238 and -308 genotype. The association of the TNF -308AA genotype with response to etanercept, but not infliximab, raises important questions about the mechanistic differences between these two drugs, and the potential for genotype to differentially influence treatment response. Uniquely among the TNF antagonists, etanercept binds LT- α [185], and does so with similar affinity to soluble TNF [186]. Moreover, it has been demonstrated in inflammatory bowel disease that LT- α production can be influenced by genotype at TNF -308, with the AA genotype correlating with a high secretor phenotype [187]. It is possible, therefore, that in the presence of increased quantities of both TNF- α and LT- α in patients carrying the TNF -308AA genotype, the potency of etanercept is insufficient to neutralize both cytokines, with resulting poor treatment response. There are also profound pharmacokinetic differences between etanercept (a soluble receptor) and infliximab (a chimeric human-murine mAb), with infliximab having higher peak concentrations and bioavailability, and a significantly longer half-life. As a result, the ratio of area under the curve/time over the normal dosing period in RA is significantly higher for infliximab compared with etanercept [188], reinforcing the possibility of differential effects of genotype at TNF -308 polymorphism.

Very few reports are available on association between genotype at TNF -238 polymorphism and response to anti-TNF treatment in RA although genotype at this marker has been associated with X-ray damage in RA, and increased severity of disease [116]. In a cohort, TNF -238GA genotype was associated with a poorer response to infliximab. This was not seen in the etanercept-treated patients, in whom there was also no association between TNF -238 genotype and treatment response. It is possible, therefore, that the poorer response to infliximab relates to the chance event of this group having more severe disease (a known marker of poor treatment response) than the etanercept-treated patients of similar genotype. Fabris et al. [115] reported that the -238AG genotype is absent in severe-unresponsive RA, but present in mild-responsive RA Italian subjects and suggested that -238GG homozygosity associates with severity and unresponsiveness. Genetic variations in the TNF and HLA-DRBI region have also been reported to affect the response to treatment of early RA [183]. Genotyping RA patients early in their disease course may help identify those with a poor prognosis and thus lead to a more aggressive treatment of their disease.

Future directions for research

Future studies should be undertaken using significantly larger samples of RA patients from various ethnic groups including non-Caucasians. The population should be stratified according to ethnicity, age, and gender. The diagnosis and severity of the disease should be based on uniform diagnostic criteria precisely describing the characteristic of individual with regards to symptoms, pattern, and functionality. Future studies should clearly identify the potential risk factors of the disease. Such information will ultimately support the research for developing novel and effective preventive measures, and establishing efficacious treatment/management strategies for RA.

The review in brief

Clinical question	Tumor necrosis factor (TNF)- α and - β have been shown to play a pivotal role in the pathogenesis of RA. The present review analyzes the role of TNF- α and TNF- β gene polymorphism in the pathogenesis of RA
Type of review	Narrative
Search of the literature	Medline search using the following keywords: Tumor necrosis factor, TNF- α , TNF- β , Rheumatoid arthritis, Polymorphism, Drug response to RA
Conclusions	The present review concludes that: <ul style="list-style-type: none"> • The alleles and genotypes of TNF-α and TNF-β polymorphisms are significantly associated with susceptibility to, and severity of, RA • The genetic variants of TNF-α and TNF-β polymorphisms provide a rationale to identify the population at risk of developing RA • Genotyping of TNF-α and TNF-β genes may be a useful tool for predicting response to the treatment • An important role of ethnicity in the association of TNF-α and TNF-β polymorphisms and RA has been suggested • In-depth genetic studies using larger sample from various ethnic groups are warranted
Limitations	Review of the literature showed significant discrepancies in results, which may be attributed to small sample size in most of the studies, improper stratification of RA patients, and significant variations in methods of diagnosis. The number of investigated patients has to be increased to establish the possibility of subdivision of the cohorts according their clinical symptoms, severity of disease, HLA status, and also with respect to individual genetic factors

References

1. Szekanecz Z, Koch AE. Update on synovitis. *Curr Rheumatol Rep* 2001; 3: 53-63; <http://dx.doi.org/10.1007/s11926-001-0051-0>
2. Donn RP, Barrett JH, Farhan A, et al. Cytokine gene polymorphisms and susceptibility to juvenile idiopathic arthritis. British Paediatric Rheumatology Study Group. *Arthritis Rheum* 2001; 44: 802-10; [http://dx.doi.org/10.1002/1529-0131\(200104\)44:4<802::AID-ANR136>3.3.CO;2-7](http://dx.doi.org/10.1002/1529-0131(200104)44:4<802::AID-ANR136>3.3.CO;2-7)
3. Smith AJ, Humphries SE. Cytokine and cytokine receptor gene polymorphisms and their functionality. *Cytokine Growth Factor Rev* 2009; 20: 43-59; <http://dx.doi.org/10.1016/j.cytogfr.2008.11.006>
4. Kuligowska M, Odrowaz-Sypniewska G. Role of interleukin-17 in cartilage and bone destruction in rheumatoid arthritis. *Ortop Traumatol Rehabil* 2004; 6: 235-41
5. Zwerina J, Redlich K, Schett G, et al. Pathogenesis of rheumatoid arthritis: targeting cytokines. *Ann N Y Acad Sci* 2005; 1051: 716-29; <http://dx.doi.org/10.1196/annals.1361.116>
6. Gambhir D, Lawrence A, Aggarwal A, et al. Association of tumor necrosis factor alpha and IL-10 promoter polymorphisms with rheumatoid arthritis in North Indian population. *Rheumatol Int* 2010; 30(9): 1211-7; <http://dx.doi.org/10.1007/s00296-009-1131-0>
7. Silman AJ, MacGregor AJ, Thomson W, et al. Twin concordance rates for rheumatoid arthritis: results from a nationwide study. *Br J Rheumatol* 1993; 32: 903-7; <http://dx.doi.org/10.1093/rheumatology/32.10.903>
8. Firestein GS. Evolving concepts of rheumatoid arthritis. *Nature* 2003; 423: 356-61; <http://dx.doi.org/10.1038/nature01661>
9. MacGregor AJ, Snieder H, Rigby AS, et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. *Arthritis Rheum* 2000; 43: 30-7; [http://dx.doi.org/10.1002/1529-0131\(200001\)43:1<30::AID-ANR5>3.0.CO;2-B](http://dx.doi.org/10.1002/1529-0131(200001)43:1<30::AID-ANR5>3.0.CO;2-B)
10. Criswell LA, Gregersen PK. Current understanding of the genetic aetiology of rheumatoid arthritis and likely future developments. *Rheumatology (Oxford)* 2005; 44 (S.4): iv9-13

11. Gibert M, Balandraud N, Touinssi M, et al. Functional categorization of HLA-DRB1 alleles in rheumatoid arthritis: the protective effect. *Hum Immunol* 2003; 64(10): 930-5; [http://dx.doi.org/10.1016/S0198-8859\(03\)00186-1](http://dx.doi.org/10.1016/S0198-8859(03)00186-1)
12. Tamiya G, Shinya M, Imanishi T, et al: Whole genome association study of rheumatoid arthritis using 27 039 microsatellites. *Hum Mol Genet* 2005; 14: 2305-21; <http://dx.doi.org/10.1093/hmg/ddi234>
13. Barton A, Thomson W, Ke X, et al. Re-evaluation of putative rheumatoid arthritis susceptibility genes in the post-genome wide association study era and hypothesis of a key pathway underlying susceptibility. *Hum Mol Genet* 2008; 17: 2274-9; <http://dx.doi.org/10.1093/hmg/ddn128>
14. Barton A, Thomson W, Ke X, et al. Rheumatoid arthritis susceptibility loci at chromosomes 10p15, 12q13 and 22q13. *Nat Genet* 2008; 40: 1156-9
15. Hinks A, Worthington J, Thomson W. The association of PTPN22 with rheumatoid arthritis and juvenile idiopathic arthritis. *Rheumatology (Oxford)* 2006; 45: 365-8; <http://dx.doi.org/10.1093/rheumatology/kei005>
16. Thomson W, Barton A, Ke X, et al. Rheumatoid arthritis association at 6q23. *Nat Genet* 2007; 39: 1431-33; <http://dx.doi.org/10.1038/ng.2007.32>
17. Orozco G, Abelson AK, González-Gay MA, et al. Study of functional variants of the BANK1 gene in rheumatoid arthritis. *Arthritis Rheum* 2009; 60: 372-9; <http://dx.doi.org/10.1002/art.24244>
18. Stahl EA, Raychaudhuri S, Remmers EF, et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. *Nat Genet* 2010; 42: 508-14; <http://dx.doi.org/10.1038/ng.582>
19. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. *Arthritis Rheum* 1987; 30: 1205-13; <http://dx.doi.org/10.1002/art.1780301102>
20. Deighton CM, Walker DJ, Griffiths ID, et al. The contribution of HLA to rheumatoid arthritis. *Clin Genet* 1989; 36: 178-82; <http://dx.doi.org/10.1111/j.1399-0004.1989.tb03185.x>
21. Matthey DL, González-Gay MA, Hajeer AH, et al. Association between HLA-DRB1*15 and secondary Sjögren's syndrome in patients with rheumatoid arthritis. *J Rheumatol* 2000; 27: 2611-6
22. Zapico I, Coto E, Rodríguez A, et al. A DNA polymorphism at the alpha2-macroglobulin gene is associated with the severity of rheumatoid arthritis. *J Rheumatol* 2000; 27: 2308-11
23. Constantin A, Lauwers-Cancès V, Navaux F, et al. Stromelysin 1 (matrix metalloproteinase 3) and HLA-DRB1 gene polymorphisms: Association with severity and progression of rheumatoid arthritis in a prospective study. *Arthritis Rheum* 2002; 46: 1754-62; <http://dx.doi.org/10.1002/art.10336>
24. Rodríguez-Carreón AA, Zuniga J, Hernández-Pacheco G, et al. Tumor necrosis factor-alpha -308 promoter polymorphism contributes independently to HLA alleles in the severity of rheumatoid arthritis in Mexicans. *J Autoimmun* 2005; 24: 63-8; <http://dx.doi.org/10.1016/j.jaut.2004.11.002>
25. Brun JG, Madland TM, Vedeler CA. Immunoglobulin G fc-receptor (FcgammaR) IIA, IIIA, and IIIB polymorphisms related to disease severity in rheumatoid arthritis. *J Rheumatol* 2002; 29: 1135-40
26. Baugh JA, Chitnis S, Donnelly SC, et al. A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. *Genes Immun* 2002; 3: 170-6; <http://dx.doi.org/10.1038/sj.gene.6363867>
27. Begovich AB, Carlton VE, Honigberg LA, et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. *Am J Hum Genet* 2004; 75: 330-7; <http://dx.doi.org/10.1086/422827>
28. Plenge RM, Cotsapas C, Davies L, et al. Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. *Nat Genet* 2007; 39: 1477-82; <http://dx.doi.org/10.1038/ng.2007.27>

29. Plenge RM, Seielstad M, Padyukov L, et al. TRAF1-C5 as a risk locus for rheumatoid arthritis—a genome wide study. *N Engl J Med* 2007; 357: 1199-209; <http://dx.doi.org/10.1056/NEJMoa073491>
30. Remmers EF, Plenge RM, Lee AT, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. *N Engl J Med* 2007; 357: 977-86; <http://dx.doi.org/10.1056/NEJMoa073003>
31. Raychaudhuri S, Remmers EF, Lee AT, et al. Common variants at CD40 and other loci confer risk of rheumatoid arthritis. *Nat Genet* 2008; 40: 1216-23
32. Raychaudhuri S, Thomson BP, Remmers EF, et al. Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. *Nat Genet* 2009; 41: 1313-8; <http://dx.doi.org/10.1038/ng.233>
33. Gregersen PK, Amos CI, Lee AT, et al. REL, encoding a member of the NF-kappaB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis. *Nat Genet* 2009; 41: 820-3; <http://dx.doi.org/10.1038/ng.395>
34. van Krugten MV, Huizinga TW, Kaijzel EL, et al. Association of the TNF +489 polymorphism with susceptibility and radiographic damage in rheumatoid arthritis. *Genes Immun* 1999; 1: 91-6; <http://dx.doi.org/10.1038/sj.gene.6363632>
35. Zapico I, Coto E, Rodríguez A, et al. CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis. *Genes Immun* 2000; 1: 288-9; <http://dx.doi.org/10.1038/sj.gene.6363673>
36. Buchs N, di Giovine FS, Silvestri T, et al. IL-1B and IL-1Ra gene polymorphisms and disease severity in rheumatoid arthritis: interaction with their plasma levels. *Genes Immun* 2001; 2: 222-8; <http://dx.doi.org/10.1038/sj.gene.6363766>
37. Kaijzel EL, van Dongen H, Bakker AM, et al. Relationship of polymorphisms of the Interleukin-1 gene cluster to occurrence and severity of rheumatoid arthritis. *Tissue Antigens* 2002; 59: 122-6; <http://dx.doi.org/10.1034/j.1399-0039.2002.590208.x>
38. van den Berg WB. Arguments for interleukin 1 as a target in chronic arthritis. *Ann Rheum Dis* 2000; 59(Suppl 1): i81-4; http://dx.doi.org/10.1136/ard.59.suppl_1.i81
39. Brennan FM, Maini RN, Feldmann M. TNF alpha—a pivotal role in rheumatoid arthritis? *Br J Rheumatol* 1992; 31: 293-8; <http://dx.doi.org/10.1093/rheumatology/31.5.293>
40. Feldmann M, Brennan FM, Foxwell BM, et al. The role of TNF alpha and IL-1 in rheumatoid arthritis. *Curr Dir Autoimmun* 2001; 3: 188-99; <http://dx.doi.org/10.1159/000060522>
41. Beutler B, Cerami A. The biology of cachectin/TNF-a primary mediator of the host response. *Annu Rev Immunol* 1989; 7: 625-55; <http://dx.doi.org/10.1146/annurev.iy.07.040189.003205>
42. Nedwin GE, Svedersky LP, Bringman TS, et al. Effect of interleukin 2, interferon-gamma, and mitogens on the production of tumor necrosis factors alpha and beta. *J Immunol* 1985; 135: 2492-7
43. Westendorp RG, Langermans JA, Huizinga TW, et al. Genetic influence on cytokine production and fatal meningococcal disease. *Lancet* 1997; 349: 170-3; [http://dx.doi.org/10.1016/S0140-6736\(96\)06413-6](http://dx.doi.org/10.1016/S0140-6736(96)06413-6)
44. Sharma S, Sharma A, Kumar S, et al. Association of TNF haplotypes with asthma, serum IgE levels, and correlation with serum TNF-alpha levels. *Am J Respir Cell Mol Biol* 2006; 35: 488-95
45. Sharma S, Ghosh B, Sharma SK. Association of TNF polymorphisms with sarcoidosis, its prognosis and tumour necrosis factor (TNF)-alpha levels in Asian Indians. *Clin Exp Immunol* 2008; 151: 251-9; <http://dx.doi.org/10.1165/rcmb.2006-0084OC>
46. Khanna D, Wu H, Park G, et al. Association of tumor necrosis factor α polymorphism, but not the shared epitope, with increased radiographic progression in a seropositive rheumatoid arthritis inception cohort. *Arthritis Rheum* 2006; 54: 1105-16; <http://dx.doi.org/10.1002/art.21750>
47. Chen R, Fang M, Cai Q, et al. Tumor necrosis factor alpha -308 polymorphism is associated with rheumatoid arthritis in Han population of Eastern China. *Rheumatol Int* 2007; 28: 121-6; <http://dx.doi.org/10.1007/s00296-007-0409-3>

48. Al-Rayes H, Al-Swailem R, Albelawi M, et al. TNF- α and TNF- β gene polymorphism in Saudi Rheumatoid Arthritis patients. *Clin Med Insights Arthritis Musculoskelet Disord* 2011; 4: 55-63
49. Braun N, Michel U, Ernst BP, et al. Gene polymorphism at position -308 of the tumor-necrosis-factor-alpha (TNF-alpha) in multiple sclerosis and its influence on the regulation of TNF-alpha production. *Neurosci Lett* 1996; 215: 75-8
50. Wilson AG, Gordon C, di Giovine FS, et al. A genetic association between systemic lupus erythematosus and tumor necrosis factor. *Eur J Immunol* 1994; 24: 191-5; <http://dx.doi.org/10.1002/eji.1830240130>
51. Wilson AG, Symons JA, McDowell TL, et al. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. *Proc Natl Acad Sci USA* 1997; 94: 3195-9; <http://dx.doi.org/10.1073/pnas.94.7.3195>
52. Abdallah AN, Cucchi-Mouillot P, Biteau N, et al. Analysis of the polymorphism of the tumour necrosis factor (TNF) gene and promoter and of circulating TNF-alpha levels in heart-transplant patients suffering or not suffering from severe rejection. *Eur J Immunogenet* 1999; 26: 249-55; <http://dx.doi.org/10.1046/j.1365-2370.1999.00128.x>
53. Jeong P, Kim EJ, Kim EG, et al. Association of bladder tumors and GA genotype of -308 nucleotide in tumor necrosis factor-alpha promoter with greater tumor necrosis factor-alpha expression. *Urology* 2004; 64: 1052-6; <http://dx.doi.org/10.1016/j.urology.2004.06.018>
54. Messer G, Spengler U, Jung MC, et al. Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production. *J Exp Med* 1991; 173: 209-19; <http://dx.doi.org/10.1084/jem.173.1.209>
55. Wilson AG, Di Giovine FS, Blakemore AIF, et al. Single base polymorphism in the human tumor necrosis factor alpha (TNF- α) gene detectable by NcoI restriction of PCR product. *Hum Mole Genet* 1992; 1: 353; <http://dx.doi.org/10.1093/hmg/1.5.353>
56. Galbraith GM, Pandey JP. Tumor necrosis factor alpha (TNF-alpha) gene polymorphism in alopecia areata. *Hum Genet* 1995; 96: 433-6; <http://dx.doi.org/10.1007/BF00191802>
57. Patino-Graci A, Sotillo-Pineiro E, Modesto C, et al. Analysis of the human tumour necrosis factor-alpha (TNF α) gene promoter polymorphisms in children with bone cancer. *J Med Genet* 2000; 37: 789-92; <http://dx.doi.org/10.1136/jmg.37.10.789>
58. Mosaad YM, Abdelsalam A, El-Bassiony SR. Association of tumour necrosis factor-alpha -308 G/A promoter polymorphism with susceptibility and disease profile of rheumatoid arthritis. *Int J Immunogenet* 2011; 38: 427-33; <http://dx.doi.org/10.1111/j.1744-313X.2011.01028.x>
59. Hussein YM, Mohamed RH, Pasha HF, et al. Association of tumor necrosis factor alpha and its receptor polymorphisms with rheumatoid arthritis in female patients. *Cell Immunol* 2011; 271: 192-6; <http://dx.doi.org/10.1016/j.cellimm.2011.06.023>
60. Karray FE, Bendhifallah I, BenAbdelghani K, et al. Tumor necrosis factor gene polymorphisms and susceptibility to rheumatoid arthritis in regional Tunisian population. *JIDI* 2011; 3: 30-5
61. Ozen S, Alikasifoglu M, Bakaloglu A, et al. Tumor necrosis factor α G \rightarrow A -238 and G \rightarrow A -308 polymorphisms in juvenile idiopathic arthritis. *Rheumatology* 2002; 41: 223-7; <http://dx.doi.org/10.1093/rheumatology/41.2.223>
62. Ates O, Hatem G, Hamuryudan V, et al. Tumor necrosis factor -alpha and interleukin-10 gene promoter polymorphism in Turkish rheumatoid arthritis patients. *Clin Rheumatol* 2008; 27: 1243-48; <http://dx.doi.org/10.1007/s10067-008-0893-1>
63. Rezaieyazdi Z, Afshari JT, Sandooghi M, et al. Tumor necrosis factor α -308 promoter polymorphism in patients with rheumatoid arthritis. *Rheumatol Int* 2007; 28: 189-91; <http://dx.doi.org/10.1007/s00296-007-0444-0>

64. Stojanović S, Jevtović-Stoimenov T, Stanković A, et al. Association of TNF-alpha polymorphism (-308 A/G) with high activity of rheumatoid arthritis and therapy response to Etanercept. *Srp Arh Celok Lek* 2011; 139: 784-9; <http://dx.doi.org/10.2298/SARH1112784S>
65. Fonseca JE, Carvalho, Cruzl M, et al. Polymorphism at position -308 of the tumour necrosis factor α gene and rheumatoid arthritis pharmacogenetics. *Ann Rheum Dis* 2005; 64: 793-4; <http://dx.doi.org/10.1136/ard.2004.028167>
66. Mourão AF, Caetano-Lopes J, Costa P, et al. Tumor necrosis factor-alpha -308 genotypes influence inflammatory activity and TNF-alpha serum concentrations in children with juvenile idiopathic arthritis. *J Rheumatol* 2009; 36: 837-42
67. Nemeč P, Pavkova-Goldbergova M, Stouracova M, et al. Polymorphism in the tumor necrosis factor- α gene promoter is associated with severity of rheumatoid arthritis in the Czech population. *Clin Rheumatol* 2008; 27: 59-65; <http://dx.doi.org/10.1007/s10067-007-0653-7>
68. Milterski B, Drynda S, Böschow G, et al. Complex genetic predisposition in adult and juvenile rheumatoid arthritis. *BMC Genet* 2004; 5: 2; <http://dx.doi.org/10.1186/1471-2156-5-2>
69. Schmeling H, Wagner U, Peterson A, et al. Tumor necrosis factor alpha promoter polymorphisms in patients with juvenile idiopathic arthritis. *Clin Exp Rheumatol* 2006; 24: 103-8
70. Lacki JK, Moser R, Korczowska I, et al. TNF-alpha gene polymorphism does not affect the clinical and radiological outcome of rheumatoid arthritis. *Rheumatol Int* 2000; 19: 137-40; <http://dx.doi.org/10.1007/s002960050117>
71. Pawlik A, Florczak M, Ostaneł L, et al. TNF-alpha -308 promoter polymorphism in patients with rheumatoid arthritis. *Scand J Rheumatol* 2005; 34: 22-6; <http://dx.doi.org/10.1080/03009740510026373>
72. Yen JH, Chenm CJ, Tsai WC, et al. Tumor necrosis factor promoter polymorphism in patients with rheumatoid arthritis in Taiwan. *J Rheumatol* 2001; 28: 1788-92
73. Lo SF, Huang CM, Wu MC, et al. Lack of association of tumor necrosis factor alpha gene polymorphism in patients with rheumatoid arthritis in central Taiwan. *Rheumatol Int* 2003; 23: 151-3; <http://dx.doi.org/10.1007/s00296-002-0256-1>
74. Seki N, Kamizono S, Yamada A, et al. Polymorphism in the 5'-flanking region of tumor necrosis factor-alpha gene in patients with rheumatoid arthritis. *Tissue Antigens* 1999; 54: 194-7; <http://dx.doi.org/10.1034/j.1399-0039.1999.540212.x>
75. Balog A, Gal J, Gyulai Z, et al. Tumor necrosis factor-alpha and heat-shock protein 70-2 gene polymorphisms in a family with rheumatoid arthritis. *Acta Microbiol Immunol Hung* 2004; 51: 263-9; <http://dx.doi.org/10.1556/AMicr.51.2004.3.4>
76. Cuenca J, Cuchacovich M, Perez C, et al. The -308 polymorphism in the tumor necrosis factor (TNF) gene promoter region and ex vivo lipopolysaccharide-induced TNF expression and cytotoxic activity in Chilean patients with rheumatoid arthritis. *Rheumatology* 2003; 42: 308-13; <http://dx.doi.org/10.1093/rheumatology/keg092>
77. Modesto C, Patiño-García A, Sotillo-Piñeiro E, et al. TNF-alpha promoter gene polymorphisms in Spanish children with persistent oligoarticular and systemic-onset juvenile idiopathic arthritis. *Scand J Rheumatol* 2005; 34: 451-4; <http://dx.doi.org/10.1080/03009740510026652>
78. Oregón-Romero E, Vázquez-Del Mercado M, Ruiz-Quezada SL, et al. Tumor necrosis factor alpha -308 and -238 polymorphisms in rheumatoid arthritis. Association with messenger RNA expression and sTNF-alpha. *J Investig Med* 2008; 56: 937-43; <http://dx.doi.org/10.231/JIM.0b013e318189152b>
79. Vinasco J, Beraun Y, Nieto A, et al. Polymorphism at the TNF loci in rheumatoid arthritis. *Tissue Antigen* 1997; 49: 74-8; <http://dx.doi.org/10.1111/j.1399-0039.1997.tb02715.x>
80. Reneses S, González-Escribano MF, Fernández-Suárez A, et al. The value of HLA-DRB1 shared epitope, -308 tumor necrosis factor-alpha gene promoter polymorphism, rheumatoid factor, anti-citrullinated peptide antibodies, and early erosions for predicting radiological outcome

- in recent-onset rheumatoid arthritis. *J Rheumatol* 2009; 36: 1143-9; <http://dx.doi.org/10.3899/jrheum.081075>
81. Maury CP, Liljestrom M, Laiho K, et al. Tumor necrosis factor alpha, its soluble receptor I, and -308 gene promoter polymorphism in patients with rheumatoid arthritis with or without amyloidosis: implications for the pathogenesis of nephropathy and anemia of chronic disease in reactive amyloidosis. *Arthritis Rheum* 2003; 48: 3068-76; <http://dx.doi.org/10.1002/art.11294>
 82. Cvetkovic JT, Wallberg-Jonsson S, Stegmayr B, et al. Susceptibility for and clinical manifestations of rheumatoid arthritis are associated with polymorphisms of the TNF-alpha, IL-1beta, and IL-1Ra genes. *J Rheumatol* 2002; 29: 212-9
 83. Brinkman BM, Huizinga TW, Kurban SS, et al. Tumor necrosis factor alpha gene polymorphisms in rheumatoid arthritis: association with susceptibility to, or severity of, disease? *Br J Rheumatol* 1997; 36: 516-21; <http://dx.doi.org/10.1093/rheumatology/36.5.516>
 84. Ursum J, van der Weijden MA, van Schaardenburg D, et al. IL10 GGC haplotype is positively and HLA-DQA1*05-DQB1*02 is negatively associated with radiographic progression in undifferentiated arthritis. *J Rheumatol* 2010; 37: 1431-8; <http://dx.doi.org/10.3899/jrheum.090913>
 85. Waldron-Lynch F, Adams C, Amos C, et al. Tumour necrosis factor 5' promoter single nucleotide polymorphisms influence susceptibility to rheumatoid arthritis (RA) in immunogenetically defined multiplex RA families. *Genes Immun* 2001; 2: 82-7; <http://dx.doi.org/10.1038/sj.gene.6363738>
 86. Wilson AG, de Vries N, van de Putte LB, et al. A tumour necrosis factor alpha polymorphism is not associated with rheumatoid arthritis. *Ann Rheum Dis* 1995; 54: 601-3; <http://dx.doi.org/10.1136/ard.54.7.601>
 87. Danis VA, Millington M, Hyland V, et al. Increased frequency of the uncommon allele of a tumor necrosis factor alpha polymorphism in rheumatoid arthritis and systemic lupus erythematosus. *Dis Markers* 1995; 12: 127-33
 88. Oen K, Malleson PN, Cabral DA, et al. Cytokine genotypes correlate with pain and radiologically defined joint damage in patients with juvenile rheumatoid arthritis. *Rheumatology (Oxford)* 2005; 44: 1115-21; <http://dx.doi.org/10.1093/rheumatology/keh689>
 89. Emonts M, Hazes MJ, Houwing-Duistermaat JJ, et al. Polymorphisms in genes controlling inflammation and tissue repair in rheumatoid arthritis: a case control study. *BMC Med Genet* 2011; 12: 36; <http://dx.doi.org/10.1186/1471-2350-12-36>
 90. Jiménez-Morales S, Velázquez-Cruz R, Ramírez-Bello J, et al. Tumor necrosis factor-alpha is a common genetic risk factor for asthma, juvenile rheumatoid arthritis, and systemic lupus erythematosus in a Mexican pediatric population. *Hum Immunol* 2009; 70: 251-6; <http://dx.doi.org/10.1016/j.humimm.2009.01.027>
 91. Bohanec Grabar P, Logar D, Tomsic M, et al. Genetic polymorphisms modifying oxidative stress are associated with disease activity in rheumatoid arthritis patients. *Dis Markers* 2009; 26: 41-8
 92. Lee YH, Ji JD, Song GG. Tumor necrosis factor- α promoter -308 A/G polymorphism and rheumatoid arthritis susceptibility: a meta-analysis. *J Rheumatol* 2007; 34: 43-9
 93. Aguillón JC, Cruzat A, Aravena O, et al. Could single-nucleotide polymorphisms (SNPs) affecting the tumour necrosis factor promoter be considered as part of rheumatoid arthritis evolution? *Immunobiology* 2006; 211: 75-84; <http://dx.doi.org/10.1016/j.imbio.2005.09.005>
 94. Lin HJ, Tsai FJ, Chen WC, et al. Association of tumor necrosis factor alpha -308 gene polymorphism with primary open-angle glaucoma in Chinese. *Eye* 2003; 17: 31-4; <http://dx.doi.org/10.1038/sj.eye.6700227>
 95. Mossbock G, Weger M, Moray M, et al. TNF-promoter polymorphisms and primary open-angle glaucoma. *Eye* 2006; 20: 1040-43; <http://dx.doi.org/10.1038/sj.eye.6702078>
 96. Tekeli O, Turacli ME, Egin Y, et al. Tumor necrosis factor alpha -308 gene polymorphism and psuedoexfoliation glaucoma. *Mol Vis* 2008; 14: 1815-8

97. Razeghinejad MR, Rahat F, Kamali-Sarvestani E. Association of TNFA -308 G/A and TNFRI +36 A/G gene polymorphisms with glaucoma. *Ophthalmic Res* 2009; 42: 118-24; <http://dx.doi.org/10.1159/000226108>
98. Wingerchuk D, Liu Q, Sobell J, et al. A population-based case-control study of the tumor necrosis factor alpha -308 polymorphism in multiple sclerosis. *Neurology* 1997; 49: 626-8; <http://dx.doi.org/10.1212/WNL.49.2.626>
99. Milner CR, Craig JE, Hussey ND, et al. No association between the -308 polymorphism in the tumor necrosis factor α (TNF- α) promoter region and polycystic ovaries. *Mol Hum Reprod* 1999; 5: 5-9; <http://dx.doi.org/10.1093/molehr/5.1.5>
100. Cuenca J, Perez C, Aguirre A, et al. Genetic polymorphism at position -308 in the promoter region of the tumor necrosis factor (TNF): Implications of its allelic distribution on susceptibility or resistance to diseases in the Chilean population. *Biol Res* 2001; 34: 237-41; <http://dx.doi.org/10.4067/S0716-97602001000300011>
101. Lee SC, Pu YB, Thomas GN, et al. Tumor necrosis factor alpha gene G -308A polymorphism in the metabolic syndrome. *Metabolism* 2000; 49: 1021-4; <http://dx.doi.org/10.1053/meta.2000.7704>
102. Rasmussen SK, Urhammer SA, Jensen JN, et al. The -238 and -308 G >A polymorphisms of the tumor necrosis factor alpha gene promoter are not associated with features of the insulin resistance syndrome or altered birth weight in Danish Caucasians. *J Clin Endocrinol Metab* 2000; 85: 1731-4; <http://dx.doi.org/10.1210/jc.85.4.1731>
103. Keatings VM, Cave SJ, Henry MJ, et al. A polymorphism in the tumor necrosis factor- α gene promoter region may predispose to a poor prognosis in COPD. *Chest* 2000; 118: 971-5; <http://dx.doi.org/10.1378/chest.118.4.971>
104. Mira JB, Cariou A, Grall F, et al. Association of TNF2, a TNF- α promoter polymorphism, with septic shock susceptibility and mortality. *JAMA* 1999; 282: 561-8; <http://dx.doi.org/10.1001/jama.282.6.561>
105. Hohler T, Kruger A, Gerken G, et al. A tumor necrosis factor-alpha (TNF-alpha) promoter polymorphism is associated with chronic hepatitis B infection. *Clin Exp Immunol* 1998; 11: 579-82; <http://dx.doi.org/10.1046/j.1365-2249.1998.00534.x>
106. Ishii T, Hirose H, Saito I, et al. Tumor necrosis factor alpha gene G -308A polymorphism, insulin resistance, and fasting plasma glucose in young, older, and diabetic Japanese men. *Metabolism* 2000; 49: 1616-8; <http://dx.doi.org/10.1053/meta.2000.18560>
107. Trajkov D, Arsov T, Petlichkovski A, et al. Distribution of the 22 cytokine gene polymorphisms in healthy Macedonian population. *Bratisl Lek Listy* 2009; 110: 7-17
108. Rosmond R, Chagnon M, Bouchard C, et al. G -308A polymorphism of the tumor necrosis factor alpha gene promoter and salivary cortisol secretion. *J Clin Endocrinol Metab* 2001; 86: 2178-80; <http://dx.doi.org/10.1210/jc.86.5.2178>
109. Conway DJ, Holland MJ, Bailey RL, et al. Scarring trachoma is associated with polymorphism in the tumor necrosis factor alpha (TNF-alpha) gene promoter and with elevated TNF-alpha levels in tear fluid. *Infect Immun* 1997; 65: 1003-6
110. Partsch G, Steiner G, Leeb BF, et al. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. *J Rheumatol* 1997; 24: 518-23
111. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. *Lancet* 2000; 356: 385-90; [http://dx.doi.org/10.1016/S0140-6736\(00\)02530-7](http://dx.doi.org/10.1016/S0140-6736(00)02530-7)
112. Barton A, Platt H, Salway F, et al. Polymorphisms in the tumour necrosis factor gene are not associated with severity of inflammatory polyarthritis. *Ann Rheum Dis* 2004; 63: 280-4; <http://dx.doi.org/10.1136/ard.2003.008680>

113. D'Alfonso S, Colombo G, Della Bella S, et al. Association between polymorphisms in the TNF region and systemic lupus erythematosus in the Italian population. *Tissue Antigens* 1996; 47: 551-5; <http://dx.doi.org/10.1111/j.1399-0039.1996.tb02598.x>
114. Höhler T, Kruger A, Schneider PM, et al. A TNF-alpha promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis. *J Invest Dermatol* 1997; 109: 562-5; <http://dx.doi.org/10.1111/1523-1747.ep12337469>
115. Fabris M, Di Poi E, D'Elia A, et al. Tumor necrosis factor-alpha gene polymorphism in severe and mild-moderate rheumatoid arthritis. *J Rheumatol* 2002; 29: 29-33
116. Kaijzel EL, van Krugten MV, Brinkman BM, et al. Functional analysis of a human tumor necrosis factor alpha (TNF-alpha) promoter polymorphism related to joint damage in rheumatoid arthritis. *Mol Med* 1998; 4: 724-33
117. Zeggini E, Thomson W, Kwiatkowski D, et al. Linkage and association studies of single-nucleotide polymorphism-tagged tumor necrosis factor haplotypes in juvenile oligoarthritis. *Arthritis Rheum* 2002; 46: 3304-11; <http://dx.doi.org/10.1002/art.10698>
118. Kazkaz L, Marotte H, Hamwi M, et al. Rheumatoid arthritis and genetic markers in Syrian and French populations: different effect of the shared epitope. *Ann Rheum Dis* 2007; 66: 195-201; <http://dx.doi.org/10.1136/ard.2004.033829>
119. Lee YH, Bae SC, Song GG. TNF promoter -308 A/G and -238 A/G polymorphisms and juvenile idiopathic arthritis: a meta-analysis. *Mol Biol Rep* 2012; 39: 8497-503; <http://dx.doi.org/10.1007/s11033-012-1704-y>
120. Schubert K, von Bonnsdorf H, Burke M, et al. A comprehensive candidate gene study on bronchial asthma and juvenile idiopathic arthritis. *Dis Markers* 2006; 22: 127-32
121. Low AS, Gonzalez-Gay MA, Akil M, et al. TNF +489 polymorphism does not contribute to susceptibility to rheumatoid arthritis. *Clin Exp Rheumatol* 2002; 20: 829-32
122. Maksymowych WP, Suarez-Almazor ME, Buenviaje H, et al. HLA and cytokine gene polymorphisms in relation to occurrence of palindromic rheumatism and its progression to rheumatoid arthritis. *J Rheumatol* 2002; 29: 2319-26
123. Date Y, Seki N, Kamizono S, et al. Identification of a genetic risk factor for systemic juvenile rheumatoid arthritis in the 5'-flanking region of the TNF alpha gene and HLA genes. *Arthritis Rheum* 1999; 42: 2577-82; [http://dx.doi.org/10.1002/1529-0131\(199912\)42:12<2577::AID-ANR10>3.0.CO;2-O](http://dx.doi.org/10.1002/1529-0131(199912)42:12<2577::AID-ANR10>3.0.CO;2-O)
124. Ichikawa N, Kotake S, Hakoda M, et al. Combining effects of polymorphism of tumor necrosis factor alpha 5'-flanking region and HLA-DRB1 on radiological progression in patients with rheumatoid arthritis. *Mod Rheumatol* 2009; 19: 134-9; <http://dx.doi.org/10.1007/s10165-008-0134-0>
125. Hirankarn N, Avihingsanon Y, Wongpiyabovorn J. Genetic susceptibility to SLE is associated with TNF-alpha gene polymorphism -863, but not -308 and -238, in Thai population. *Int J Immunogenet* 2007; 34: 425-30; <http://dx.doi.org/10.1111/j.1744-313X.2007.00715.x>
126. Bayraktar S, Kasapcopur O, Arisoy N, et al. Tumor necrosis factor-alpha polymorphism and susceptibility to juvenile idiopathic arthritis. *Pediatric Rheumatology* 2008; 6(S1): 6. <http://dx.doi.org/10.1186/1546-0096-6-S1-P6>
127. Udalova IA, Richardson A, Ackerman H, et al. Association of accelerated erosive rheumatoid arthritis with a polymorphism that alters NF-kappaB binding to the TNF promoter region. *Rheumatology (Oxford)* 2002; 41: 830-1; <http://dx.doi.org/10.1093/rheumatology/41.7.830>
128. Martínez A, Fernández-Arquero M, Pascual-Salcedo D, et al. Primary association of tumor necrosis factor-region genetic markers with susceptibility to rheumatoid arthritis. *Arthritis Rheum* 2000; 43: 1366-70; [http://dx.doi.org/10.1002/1529-0131\(200006\)43:6<1366::AID-ANR21>3.0.CO;2-S](http://dx.doi.org/10.1002/1529-0131(200006)43:6<1366::AID-ANR21>3.0.CO;2-S)

129. Gomez LM, Ruiz-Narváez EA, Pineda-Tamayo R, et al. TNF microsatellites polymorphism is associated with rheumatoid arthritis. Confirming evidence in northwestern Colombians. *Clin Exp Rheumatol* 2007; 25: 443-8
130. Agrawal C, Raghav SK, Gupta B, et al. Tumor necrosis factor-alpha microsatellite polymorphism association with rheumatoid arthritis in Indian patients. *Arch Med Res* 2005; 36: 555-9; <http://dx.doi.org/10.1016/j.arcmed.2005.03.035>
131. Hamann A, Mantzoros C, Vidal-Puig A, et al. Genetic variability in the TNF-alpha promoter is not associated with type II diabetes mellitus (NIDDM). *Biochem Biophys Res Commun* 1995; 211: 833-9; <http://dx.doi.org/10.1006/bbrc.1995.1887>
132. Mullighan CG, Fanning GC, Chapel HM, et al. TNF and lymphotoxin-alpha polymorphisms associated with common variable immunodeficiency: role in the pathogenesis of granulomatous disease. *J Immunol* 1997; 159: 6236-41
133. Verweij CL. Tumour necrosis factor gene polymorphisms as severity markers in rheumatoid arthritis. *Ann Rheum Dis* 1999; 58: I20-I26; <http://dx.doi.org/10.1136/ard.58.2008.i20>
134. Higuchi T, Seki N, Kamizono S, et al. Polymorphism of the 5'-flanking region of the human tumor necrosis factor (TNF)-alpha gene in Japanese. *Tissue Antigens* 1998; 51: 605-12; <http://dx.doi.org/10.1111/j.1399-0039.1998.tb03002.x>
135. Lv K, Chen R, Cai Q, et al. Effects of a single nucleotide polymorphism on the expression of human tumor necrosis factor-alpha. *Scand J Immunol* 2006; 4: 164-9; <http://dx.doi.org/10.1111/j.1365-3083.2006.01786.x>
136. Skoog T, van't Hooft FM, Kallin B, et al. A common functional polymorphism (C->A substitution at position -863) in the promoter region of the tumour necrosis factor-alpha (TNF-alpha) gene associated with reduced circulating levels of TNF-alpha. *Hum Mol Genet* 1999; 8: 1443-9; <http://dx.doi.org/10.1093/hmg/8.8.1443>
137. van Heel DA, Udalova IA, De Silva AP, et al. Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF(-kappa)B transcription factors. *Hum Mol Genet* 2002; 11: 1281-9; <http://dx.doi.org/10.1093/hmg/11.11.1281>
138. Panoulas VF, Nikas SN, Smith JP, et al. Lymphotoxin 252A>G polymorphism is common and associates with myocardial infarction in patients with rheumatoid arthritis. *Ann Rheum Dis* 2008; 67: 1550-6; <http://dx.doi.org/10.1136/ard.2007.082594>
139. Boraska V, Zeggini E, Groves CJ, et al. Family-based analysis of tumor necrosis factor and lymphotoxin-alpha tag polymorphism with type 1 diabetes in the population of South Croatia. *Hum Immunol* 2009; 70: 195-9; <http://dx.doi.org/10.1016/j.humimm.2008.12.010>
140. Stüber F, Petersen M, Bokelmann F, et al. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. *Crit Care Med* 1996; 24: 381-4; <http://dx.doi.org/10.1097/00003246-199603000-00004>
141. Takeuchi F, Nabeta H, Hong GH, et al. The genetic contribution of the TNFa11 microsatellite allele and the TNFb + 252*2 allele in Japanese RA. *Clin Exp Rheumatol* 2005; 23: 494-8
142. Al-Swailem R, Al-Rayes H, Sobki S, et al. HLA-DRB1 association in Saudi rheumatoid arthritis patients. *Rheumatol Int* 2006; 26: 1019-24; <http://dx.doi.org/10.1007/s00296-006-0119-2>
143. Santos MJ, Fernandes D, Caetano-Lopes J, et al. Lymphotoxin- α 252 A>G polymorphism: a link between disease susceptibility and dyslipidemia in rheumatoid arthritis? *J Rheumatol* 2011; 38: 1244-9; <http://dx.doi.org/10.3899/jrheum.101170>
144. Kula D, Jurecka-Tuleja B, Gubala E, et al. Association of polymorphism of LT alpha and TNF genes with Graves' disease. *Folia Histochem Cytobiol* 2001; 39: 77-8
145. Medcraft J, Hitman GA, Sachs JA, et al. Autoimmune renal disease and tumor necrosis factor beta gene polymorphism. *Clin Nephrol* 1993; 40: 63-8

146. Zelano G, Lino MM, Evoli A, et al. Tumor necrosis factor beta gene polymorphisms in myasthenia gravis. *Eur J Immunogenet* 1998; 25: 403-8; <http://dx.doi.org/10.1046/j.1365-2370.1998.00129.x>
147. Albuquerque RV, Hayden CM, Palmer LJ, et al. Association of polymorphisms within the tumor necrosis factor (TNF) genes and childhood asthma. *Clin Exp Allergy* 1998; 28: 578-84; <http://dx.doi.org/10.1046/j.1365-2222.1998.00273.x>
148. Lu LY, Cheng HH, Sung PK, et al. Tumor necrosis factor-beta +252A polymorphism is associated with systemic lupus erythematosus in Taiwan. *J Formos Med Assoc* 2005; 104: 563-70
149. Pandey JP, Takeuchi F. TNF- α and TNF- β gene polymorphisms in systemic sclerosis – a possible link to insulin-dependent diabetes mellitus. *Hum Immunol* 1999; 60: 1128-30; [http://dx.doi.org/10.1016/S0198-8859\(99\)00105-6](http://dx.doi.org/10.1016/S0198-8859(99)00105-6)
150. Vasku V, Vasku A, Izakovicova Holla L, et al. Polymorphisms in inflammation genes (angiotensinogen, TAP1 and TNF-beta) in psoriasis. *Arch Dermatol Res* 2000; 292: 531-4; <http://dx.doi.org/10.1007/s004030000176>
151. Wantanabe E, Buchman TG, Hirasawa H, et al. Association between lymphotoxin- α (tumor necrosis factor- β) intron polymorphism and predisposition to severe sepsis is modified by gender and age. *Crit Care Med* 2010; 38: 181-93; <http://dx.doi.org/10.1097/CCM.0b013e3181bc805d>
152. Tiancha H, Huiqin W, Jiyong J, et al. Association between lymphotoxin- α intron +252 polymorphism and sepsis: A meta-analysis. *Scand J Infect Dis* 2011; 43: 436-47; <http://dx.doi.org/10.3109/00365548.2011.562528>
153. Vandevyver C, Raus P, Stinissen P, et al. Polymorphism of the tumour necrosis factor beta gene in multiple sclerosis and rheumatoid arthritis. *Eur J Immunogenet* 1994; 21: 377-82; <http://dx.doi.org/10.1111/j.1744-313X.1994.tb00208.x>
154. Zake LN, Cimkina I, Rumba I, et al. Major histocompatibility complex class I chain related (MIC) A gene, TNF α microsatellite alleles and TNFB alleles in juvenile idiopathic arthritis patients from Latvia. *Hum Immunol* 2002; 63: 418-23; [http://dx.doi.org/10.1016/S0198-8859\(02\)00385-3](http://dx.doi.org/10.1016/S0198-8859(02)00385-3)
155. Bidwell J, Keen L, Gallagher G, et al. Cytokine gene polymorphism in human disease: on-line databases. *Genes Immun* 1999; 1: 3-19; <http://dx.doi.org/10.1038/sj.gene.6363645>
156. Chen YF, Jobanputra P, Barton P, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. *Health Technol Assess* 2006; 10: 1-229
157. Moreland LW, Emery P. TNF- α Inhibition in the Treatment of Rheumatoid Arthritis. London: Taylor & Francis (Martin Dunitz), 2003; p. 192
158. Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. *Arthritis Res Ther* 2009; 11(Suppl 1): S1; <http://dx.doi.org/10.1186/ar2666>
159. Liu C, Batliwalla F, Li W, et al. Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. *Mol Med* 2008; 14: 575-81
160. Maxwell JR, Potter C, Hyrich KL, et al. Association of the tumour necrosis factor -308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. *Hum Mol Genet* 2008; 17: 3532-8; <http://dx.doi.org/10.1093/hmg/ddn245>
161. Skapenko A, Prots I, Schulze-Koops H. Prognostic factors in rheumatoid arthritis in the era of biologic agents. *Nat Rev Rheumatol* 2009; 5: 491-6; <http://dx.doi.org/10.1038/nrrheum.2009.157>
162. Plenge RM, Criswell LA. Genetic variants that predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis: current challenges and future directions. *Curr Opin Rheumatol* 2008; 20: 145-52; <http://dx.doi.org/10.1097/BOR.0b013e3282f5135b>

163. Zeng Z, Duan Z, Zhang T, et al. Association between tumor necrosis factor- α (TNF- α) promoter -308 G/A and response to TNF- α blockers in rheumatoid arthritis: a meta-analysis. *Mod Rheumatol* 2012 Jul 4 [Epub ahead of print]; <http://dx.doi.org/10.1007/s10165-012-0699-5>
164. Lee YH, Rho YH, Choi SJ, et al. Association of TNF-alpha -308G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis. *Rheumatol Int* 2006; 27: 157-61; <http://dx.doi.org/10.1007/s00296-006-0175-7>
165. Llanos C, Soto L, Sabugo F, et al. The influence of -238 and -308 TNF alpha polymorphisms on the pathogenesis and response to treatment in rheumatoid arthritis. *Rev Med Chil* 2005; 133: 1089-95
166. O'Rielly DD, Roslin NM, Beyene J, et al. TNF-alpha -308 G/A polymorphism and responsiveness to TNF-alpha blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis. *Pharmacogenomics J* 2009; 9: 161-7; <http://dx.doi.org/10.1038/tpj.2009.7>
167. Lee YH, Ji JD, Bae SC, et al. Associations between tumor necrosis factor-alpha (TNF-alpha) -308 and -238 G/A polymorphisms and shared epitope status and responsiveness to TNF-alpha blockers in rheumatoid arthritis: a meta-analysis update. *J Rheumatol* 2010; 37: 740-6; <http://dx.doi.org/10.3899/jrheum.090707>
168. Seitz M, Wirthmuller U, Moller B, et al. The -308 tumor necrosis factor- α gene polymorphism predicts therapeutic response to TNF α -blockers in rheumatoid arthritis and spondyloarthritis patients. *Rheumatology* 2007; 46: 93-6; <http://dx.doi.org/10.1093/rheumatology/kel175>
169. Cimaz R, Cazalis MA, Reynaud C, et al. IL1 and TNF gene polymorphisms in patients with juvenile idiopathic arthritis treated with TNF inhibitors. *Ann Rheum Dis* 2007; 66: 900-4; <http://dx.doi.org/10.1136/ard.2006.067454>
170. Pavy S, Toonen EJ, Miceli-Richard C, et al. Tumour necrosis factor alpha -308G->A polymorphism is not associated with response to TNF alpha blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis. *Ann Rheum Dis* 2010; 69: 1022-8; <http://dx.doi.org/10.1136/ard.2009.117622>
171. Mugnier B, Balandraud N, Darque A, et al. Polymorphism at position -308 of the tumor necrosis factor α gene influences outcome of infliximab therapy in rheumatoid arthritis. *Arthritis Rheum* 2003; 48: 1849-52; <http://dx.doi.org/10.1002/art.11168>
172. Guis S, Balandraud N, Bouvenot J, et al. Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis. *Arthritis Rheum* 2007; 57: 1426-30; <http://dx.doi.org/10.1002/art.23092>
173. Cuchacovich M, Ferreira L, Aliste M, et al. Tumour necrosis factor-alpha (TNF-alpha) levels and influence of -308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis. *Scand J Rheumatol* 2004; 33: 228-32; <http://dx.doi.org/10.1080/03009740410005863>
174. Cuchacovich M, Soto L, Edwardes M, et al. Tumour necrosis factor (TNF)alpha -308 G/G promoter polymorphism and TNF alpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis. *Scand J Rheumatol* 2006; 35: 435-40; <http://dx.doi.org/10.1080/03009740600904284>
175. Soto L, Sabugo F, Catalan D, et al. The presence of anti-citrullinated protein antibodies (ACPA) does not affect the clinical response to adalimumab in a group of RA patients with the tumor necrosis factor (TNF) α -308 G/G promoter polymorphism. *Clin Rheumatol* 2011; 30: 391-5; <http://dx.doi.org/10.1007/s10067-011-1679-4>
176. Padyukov L, Lampa J, Heimbürger M, et al. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. *Ann Rheum Dis* 2003; 62: 526-9; <http://dx.doi.org/10.1136/ard.62.6.526>

177. Schmeling H, Horneff G. Tumour necrosis factor alpha promoter polymorphisms and etanercept therapy in juvenile idiopathic arthritis. *Rheumatol Int* 2007; 27: 383-6; <http://dx.doi.org/10.1007/s00296-006-0208-2>
178. Basic J, Pavlovic D, Jevtovic-Stoimenov T, et al. Etanercept reduces matrix metalloproteinase-9 level in children with polyarticular juvenile idiopathic arthritis and TNF-alpha -308GG genotype. *J Physiol Biochem* 2010; 66: 173-80; <http://dx.doi.org/10.1007/s13105-010-0022-x>
179. Pinto JA, Rego I, Rodríguez-Gomez M, et al. Polymorphisms in genes encoding tumor necrosis factor-alpha and HLA-DRB1 are not associated with response to infliximab in patients with rheumatoid arthritis. *J Rheumatol* 2008; 35: 177-8
180. de Paz B, Alperi-López M, Ballina-García FJ, et al. Interleukin 10 and tumor necrosis factor-alpha genotypes in rheumatoid arthritis--association with clinical response to glucocorticoids. *J Rheumatol* 2010; 37: 503-11; <http://dx.doi.org/10.3899/jrheum.090566>
181. Kang CP, Lee KW, Yoo DH, et al. The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. *Rheumatology (Oxford)* 2005; 44: 547-52; <http://dx.doi.org/10.1093/rheumatology/keh550>
182. Pawlik A, Herczyńska M, Kurzawski M, et al. IL-1beta, IL-6, and TNF gene polymorphisms do not affect the treatment outcome of rheumatoid arthritis patients with leflunomide. *Pharmacol Rep* 2009; 61: 281-7
183. Criswell LA, Lum RF, Turner KN, et al. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. *Arthritis Rheum* 2004; 50: 2750-6; <http://dx.doi.org/10.1002/art.20469>
184. Smolen JS, Breedveld FC, Burmester GR, et al. Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis. *Ann Rheum Dis* 2000; 59: 504-5; <http://dx.doi.org/10.1136/ard.59.7.504>
185. Gudbrandsdottir S, Larsen R, Sorensen LK, et al. TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis. *Clin Exp Rheumatol* 2004; 22: 118-24
186. Scallon BJ, Moore MA, Trinh H, et al. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. *Cytokine* 1995; 7: 251-9; <http://dx.doi.org/10.1006/cyto.1995.0029>
187. Bouma G, Crusius JB, Oudkerk Pool M, et al. Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. *Scand J Immunol* 1996; 43: 456-63; <http://dx.doi.org/10.1046/j.1365-3083.1996.d01-65.x>
188. Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ? *Semin Arthritis Rheum* 2005; 34(5 Suppl1): 12-8; <http://dx.doi.org/10.1016/j.semarthrit.2005.01.004>